Actuate Therapeutics Identifies Biomarkers in Treatment of Metastatic Pancreatic Cancer in Phase 2 Trial

MT Newswires Live

Jun 20, 2025

Actuate Therapeutics (ACTU) said Friday that its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer demonstrated the use of machine learning and statistical models to predict overall survival based on pre-dose plasma biomarkers.

The analysis identified seven biomarkers as "uniquely significant" predictors of favorable survival in the elraglusib-treated cohort, the biopharmaceutical company said.

The biomarker CXCL2 had an inverse survival trend compared to the gemcitabine/nab-paclitaxel control arm, "highlighting the potential of elraglusib to favorably affect the immune microenvironment," Actuate said.

The company said it plans to test the identified biomarkers prospectively in future trials.

Shares were 5.8% higher in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2544120502"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544120502\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544120502?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-20 21:17","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544120502","market":"nz","top_or_hot":-1,"title":"Actuate Therapeutics Identifies Biomarkers in Treatment of Metastatic Pancreatic Cancer in Phase 2 Trial","media":"MT Newswires Live","content":"<html><body><p> Actuate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ACTU) said Friday that its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer demonstrated the use of machine learning and statistical models to predict overall survival based on pre-dose plasma biomarkers.</p><p>The analysis identified seven biomarkers as \"uniquely significant\" predictors of favorable survival in the elraglusib-treated cohort, the biopharmaceutical company said.</p><p>The biomarker CXCL2 had an inverse survival trend compared to the gemcitabine/nab-paclitaxel control arm, \"highlighting the potential of elraglusib to favorably affect the immune microenvironment,\" Actuate said.</p><p>The company said it plans to test the identified biomarkers prospectively in future trials.</p><p>Shares were 5.8% higher in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actuate Therapeutics Identifies Biomarkers in Treatment of Metastatic Pancreatic Cancer in Phase 2 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActuate Therapeutics Identifies Biomarkers in Treatment of Metastatic Pancreatic Cancer in Phase 2 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-06-20 21:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Actuate <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (ACTU) said Friday that its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer demonstrated the use of machine learning and statistical models to predict overall survival based on pre-dose plasma biomarkers.</p><p>The analysis identified seven biomarkers as \"uniquely significant\" predictors of favorable survival in the elraglusib-treated cohort, the biopharmaceutical company said.</p><p>The biomarker CXCL2 had an inverse survival trend compared to the gemcitabine/nab-paclitaxel control arm, \"highlighting the potential of elraglusib to favorably affect the immune microenvironment,\" Actuate said.</p><p>The company said it plans to test the identified biomarkers prospectively in future trials.</p><p>Shares were 5.8% higher in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2544120502","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544120502","pubTimestamp":1750425447,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Actuate Therapeutics  said Friday that its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer demonstrated the use of machine learning and statistical models to predict overall survival based on pre-dose plasma biomarkers.The analysis identified seven biomarkers as \"uniquely significant\" predictors of favorable survival in the elraglusib-treated cohort, the biopharmaceutical company said.The biomarker CXCL2 had an inverse survival trend compared to the gemcitabine/nab-paclitaxel control arm, \"highlighting the potential of elraglusib to favorably affect the immune microenvironment,\" Actuate said.The company said it plans to test the identified biomarkers prospectively in future trials.Shares were 5.8% higher in recent premarket activity.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药","ACTU":"Actuate Therapeutics Inc"},"translate_title":"Actuate Therapeutics在2期试验中确定了治疗转移性胰腺癌的生物标志物","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACTU":1,"LENZ":1},"content_text":"Actuate Therapeutics (ACTU) said Friday that its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel in first-line metastatic pancreatic cancer demonstrated the use of machine learning and statistical models to predict overall survival based on pre-dose plasma biomarkers.The analysis identified seven biomarkers as \"uniquely significant\" predictors of favorable survival in the elraglusib-treated cohort, the biopharmaceutical company said.The biomarker CXCL2 had an inverse survival trend compared to the gemcitabine/nab-paclitaxel control arm, \"highlighting the potential of elraglusib to favorably affect the immune microenvironment,\" Actuate said.The company said it plans to test the identified biomarkers prospectively in future trials.Shares were 5.8% higher in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}